The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the ...
Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related ...
Preclinical results from St. Jude Children’s Research Hospital show that an RNA-targeted therapy can restore function in a ...
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs ...
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...
Patients treated with high-dose BIIB080 saw positive trends on the global Clinical Dementia Rating Sum of Boxes, Mini-Mental State Exam cognitive scales and Functional Activities Questionnaire at week ...
Collaboration leverages Alloy's platform to accelerate the development of innovative oligonucleotide therapeutics - Latest collaboration between the two companies builds on past work together, ...
Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...
Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful closing of an oversubscribed $54 million Series A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results